Although previous studies have shown that GPR17 non-selective antagonists may be beneficial in limiting brain damage in acute conditions [12,13] we postulate that, in chronic diseases such as MS, GPR17 agonists may promote oligodendrocyte maturation and foster myelination, by promoting its signalling and the consequent receptor downregulation [24,25]. Here, GPR17 is linked to myeloid sarcoma.